A Recent Update on Therapeutics to Treat Emerging n-COVID 19: A Review

Author(s): Sumel Ashique, Navjot K. Sandhu*, Sk. Niyamul Haque, Kartick Koley

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Volume 2 , Issue 7 , 2021

Article ID: e250621188724
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


A coronavirus is a group of nonsegmented, single-stranded, enveloped viruses having positive RNA genomes. This virus was first described in 1931, and the first coronavirus was isolated (HCoV-229E) from humans in 1965. People be-come infected with four human coronavirus strains: 229E, NL63, OC43, and HKU1, which cause respiratory associated problems such as SARS and MERS. Lately, a new version of a strain called SARD-CoV-2 has been found. WHO called it novel coronavirus-infected pneumonia (NCIP) and later officially renamed as COVID-19 on 11th Feb 2020. The outbreak began in Wuhan, Hubei, China, in Dec 2019 and from now the outbreak becomes pandemic. Here, we have reviewed various categories of therapeutics, vaccines, and clinically investigated drugs to treat and prevent n-COVID-19. Till now, no specific FDA approved drugs or vaccines are available against n-COVID-19. Several options can be visualized to control or prevent emerging infections, including antivirals, immunomodulators, interferons, vaccines, monoclonal antibodies, and bio- molecules. Given the urgency of the outbreak, we have discussed some potential existing therapeutics for treating n-COVID-19.

Keywords: n-COVID-19, therapeutics, vaccines, coronaviruses, monoclonal antibodies, RNA vaccine.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 04 December, 2020
Article ID: e250621188724
Pages: 16
DOI: 10.2174/2666796701999201204123259

Article Metrics

PDF: 12